Anavex Life Sciences Corp (AVXL)

[falconer66a]

Again, the profound blarcamesine safety factor.

We get approval for RETT and then the Aussies approve us for ALZ. And PDD gets approved. Our Safety factor has been near perfect in all tests for all of the above.

The blarcamesine “safety factor” should not be neglected; it’s major.

Think not? Look up the drug info on any of the prescription drugs acting in the central nervous system, and compare their side effects and dosage warnings (to physicians), compared to the infrequent and very mild side effects of blarcamesine: a few headaches or an upset stomach, in most cases spontaneously resolving after a short period. No disruption of genes, hormones, or other biochemical processes, etc.

When very reactive chemicals enter the brain or nerves (after passing through the blood-brain barrier; often requiring large doses to do this, to get some of the drug into the target tissues) all sorts of biochemical or genetic disruptions are induced. For CNS diseases, for the few drugs currently available, prescribing physicians must always carefully balance dosages against the adverse events (side effects) the drugs are noted for. The drug may reduce certain CNS disease symptoms, but at the same time induce all sorts side effects.

With blarcamesine, the dosage-against-side effects calculation will be simple. Simply not much of a factor.

And, yes, in every single murine and human test of blarcamesine, side effects have been either minimal and mild, or simply absent.

All of that was one of the first things I wanted to learn about, when I learned of Anavex 2-73 (blarcamesine). What side effects appear at various dosages? I was astonished to find virtually none that paralleled those of existing CNS drugs. Simply, blarcamesine does not disrupt other, non-target molecules or reaction pathways. It sticks (literally) to the molecules that can benefit; not to others.